LOS ANGELES, July 31, 2023 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against ImmunityBio, Inc. ("ImmunityBio" or the "Company") (NASDAQ: IBRX).
Class Period: May 23, 2022 – May 10, 2023
Lead Plaintiff Deadline:August 29, 2023
If you are a shareholder who suffered a loss, click here to participate.
The complaint filed alleges that, throughout the Class Period, Defendants failed to disclose to investors that: (1) ImmunityBio conducted insufficient due diligence to discover, or
else did discover and ignored, Good Manufacturing Practice ("GMP") deficiencies at its third-party CMOs for Anktiva; (2) one or more of the Company's third-party CMOs for Anktiva did in
fact suffer from GMP deficiencies; (3) the foregoing deficiencies was likely to cause the FDA to reject the Anktiva BLA in its present form; (4) accordingly, the Company overstated the regulatory approval prospects for the Anktiva BLA; and (5) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.
Follow us for updates on Twitter: twitter.com/FRC_LAW.
To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to info@frankcruzlaw.com, or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number, and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
View original content:https://www.prnewswire.com/news-releases/ibrx-investors-have-opportunity-to-lead-immunitybio-inc-securities-fraud-lawsuit-301888709.html
SOURCE The Law Offices of Frank R. Cruz, Los Angeles
